Karyopharm Therapeutics
KPTI
146 hedge funds and large institutions have $1.13B invested in Karyopharm Therapeutics in 2019 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 41 increasing their positions, 39 reducing their positions, and 11 closing their positions.
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
373% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 11
101% more capital invested
Capital invested by funds: $563M → $1.13B (+$567M)
38% more funds holding
Funds holding: 106 → 146 (+40)
5% more call options, than puts
Call options by funds: $16.5M | Put options by funds: $15.6M
5% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 39
0.04% less ownership
Funds ownership: 6.3% → 6.26% (-0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$30.2M |
| 2 |
D.E. Shaw & Co
New York
|
+$14.2M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$11.8M |
| 4 |
Two Sigma Investments
New York
|
+$10.6M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$5.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$63.6M |
| 2 |
Millennium Management
New York
|
-$18.4M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$14.4M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$13.7M |
| 5 |
ECP
Elk Creek Partners
Denver,
Colorado
|
-$11.7M |
KPTI Hedge Fund Activity: Q4 2019 in Review
146 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2019, worth a combined $1.13B — up 101% from $563M a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new KPTI positions and 11 closed out — a net gain of 41 holders — while 41 added to existing stakes and 39 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $30.2M. The largest seller was Wellington Management Group, cutting an estimated $63.6M.
- 146 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2019, up from 106 in Q3 2019.
- Funds reported $1.13B of Karyopharm Therapeutics stock for Q4 2019, up 101% quarter-over-quarter.
- 52 funds opened new Karyopharm Therapeutics positions in Q4 2019 and 11 closed out, a net change of +41 holders.
- The largest Karyopharm Therapeutics buyer in Q4 2019 was Adage Capital Partners, an estimated $30.2M added.
- The largest Karyopharm Therapeutics seller in Q4 2019 was Wellington Management Group, an estimated $63.6M sold.
Based on aggregated 13F filings for Q4 2019.